Cilostazol-d4

CAT: 0804-HY-17464S1-01Size: 1 mgDry Ice: NoHazardous: No
CAT#:0804-HY-17464S1-01Size:1 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
Cilostazol-d4 is deuterium labeled Cilostazol. Cilostazol (OPC 13013) is a potent and selective inhibitor of phosphodiesterase (PDE) 3A, the isoform of PDE 3 in the cardiovascular system, with an IC50 of 0.2 μM[1][2].
CAS Number
[1215541-47-1]
Product Name Alternative
OPC-13013-d4
UNSPSC
12352005
Target
Autophagy; Isotope-Labeled Compounds; Phosphodiesterase (PDE)
Type
Isotope-Labeled Compounds
Related Pathways
Autophagy; Metabolic Enzyme/Protease; Others
Applications
Cancer-programmed cell death
Field of Research
Cardiovascular Disease; Cancer
Solubility
10 mM in DMSO
Smiles
O=C1NC2=CC=C(C=C2CC1)OCCCCC3=NN=NN3C4C([2H])([2H])CCCC4([2H])[2H]
Molecular Formula
C20H23D4N5O2
Molecular Weight
373.49
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]Minami N, et al. Inhibition of shear stress-induced platelet aggregation by cilostazol, a specific inhibitor of cGMP-inhibited phosphodiesterase, in vitro and ex vivo. Life Sci. 1997;61 (25) :PL 383-9.|[3]Saito S, et al. Cilostazol attenuates hepatic stellate cell activation and protects mice against carbon tetrachloride-induced liver fibrosis. Hepatol Res. 2013 Apr 19.|[4]Schr?r K. The pharmacology of cilostazol. Diabetes Obes Metab. 2002 Mar;4 Suppl 2:S14-9.|[5]Ye YL, et al. Cilostazol, a phosphodiesterase 3 inhibitor, protects mice against acute and late ischemic brain injuries.Eur J Pharmacol. 2007 Feb 14;557 (1) :23-31. Epub 2006 Nov 10.
Shipping Conditions
Room temperature
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported

Popular Products